{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:17:05Z","timestamp":1778570225509,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF 2016\\u2013 02363995"],"award-info":[{"award-number":["RF 2016\\u2013 02363995"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["02363995"],"award-info":[{"award-number":["02363995"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejca.2021.11.003","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T16:08:13Z","timestamp":1639584493000},"page":"55-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment"],"prefix":"10.1016","volume":"161","author":[{"given":"Antonino","family":"Ditto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7066-473X","authenticated-orcid":false,"given":"Loris","family":"De Cecco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7535-7715","authenticated-orcid":false,"given":"Biagio","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4863-1747","authenticated-orcid":false,"given":"Fabio","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Leone Roberti Maggiore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Bogani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-2264","authenticated-orcid":false,"given":"Paolo","family":"Chiodini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Tomassetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Raspagliesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9664-6871","authenticated-orcid":false,"given":"Delia","family":"Mezzanzanica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-4630","authenticated-orcid":false,"given":"Marina","family":"Bagnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.11.003_bib1","first-page":"280","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.ejca.2021.11.003_bib2","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"Ca - Cancer J Clin"},{"key":"10.1016\/j.ejca.2021.11.003_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ygyno.2009.10.074","article-title":"Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"116","author":"Chan","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2021.11.003_bib4","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jnci\/djq149","article-title":"Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial","volume":"102","author":"Trimbos","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2021.11.003_bib5","first-page":"CD004706","article-title":"Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer","volume":"2015","author":"Lawrie","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejca.2021.11.003_bib6","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/annonc\/mdu116","article-title":"ICON1 collaborators, Optimal treatment of early-stage ovarian cancer","volume":"25","author":"Collinson","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.11.003_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ijgo.12769","article-title":"Predictive factors of recurrence in patients with early-stage epithelial ovarian cancer","volume":"145","author":"Ditto","year":"2019","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.ejca.2021.11.003_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12094-011-0619-8","article-title":"Early-stage ovarian cancer management: still a challenge","volume":"13","author":"Gonz\u00e1lez Mart\u00edn","year":"2011","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ejca.2021.11.003_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/cells8030200","article-title":"Gynecological cancers translational, research implementation, and harmonization: gynecologic cancer InterGroup consensus and still open questions","volume":"8","author":"Bagnoli","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejca.2021.11.003_bib10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2021.11.003_bib11","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1200\/JCO.2009.24.0317","article-title":"MicroRNAs in cancer: small molecules with a huge impact","volume":"27","author":"Iorio","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.11.003_bib12","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"Lu","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2021.11.003_bib13","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(16)30108-5","article-title":"Multicentre Italian Trials in Ovarian cancer (MITO) translational group, Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study","volume":"17","author":"Bagnoli","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.11.003_bib14","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/cancers13071544","article-title":"Prognostic evidence of the miRNA-based ovarian cancer signature MiROvaR in independent datasets","volume":"13","author":"De Cecco","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2021.11.003_bib15","doi-asserted-by":"crossref","first-page":"51862","DOI":"10.1371\/journal.pone.0051862","article-title":"Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization","volume":"7","author":"Budczies","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2021.11.003_bib16","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO Ovarian Cancer Consensus Conference Working Group, ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.11.003_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jnci\/95.2.113","volume":"95","author":"Trimbos","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2021.11.003_bib18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jnci\/95.2.105","volume":"95","author":"Trimbos","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2021.11.003_bib19","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3390\/cells8121554","article-title":"Transcriptional characterization of stage I epithelial ovarian cancer: a multicentric study","volume":"8","author":"Calura","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ejca.2021.11.003_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(11)70012-2","article-title":"Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections","volume":"12","author":"Marchini","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.11.003_bib21","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/annonc\/mdw210","article-title":"A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment","volume":"27","author":"Calura","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.11.003_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4161\/rna.5.3.6558","article-title":"The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis","volume":"5","author":"Korpal","year":"2008","journal-title":"RNA Biol"},{"key":"10.1016\/j.ejca.2021.11.003_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2014.05.022","article-title":"Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics","volume":"351","author":"Koutsaki","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ejca.2021.11.003_bib24","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature15748","article-title":"Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance","volume":"527","author":"Fischer","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2021.11.003_bib25","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41588-018-0179-8","article-title":"Copy number signatures and mutational processes in ovarian carcinoma","volume":"50","author":"Macintyre","year":"2018","journal-title":"Nat Genet"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921012144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:52:57Z","timestamp":1778568777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921012144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":25,"alternative-id":["S0959804921012144"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.11.003","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}